Working… Menu
Trial record 47 of 228 for:    yeast

Statin Therapy Vs. Therapeutic Lifestyle Changes and Supplements

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00365742
Recruitment Status : Completed
First Posted : August 17, 2006
Last Update Posted : August 17, 2006
Information provided by:
Chestnut Hill Health System

Brief Summary:

Randomized trial in a primary prevention population

  • all participants have high LDL cholesterol

Group one will take simvastatin 40 mg/day Group Two will make therapeutic lifestyle changes,and take supplements consisting of red yeast rice and fish oil

Condition or disease Intervention/treatment Phase
Hyperlipidemia Drug: simvastatin Drug: red yeast rice Drug: pharmaceutical grade fish oil Behavioral: therapeutic lifestyle changes Not Applicable

Detailed Description:
This is a randomized primary prevention trial to compare the LDL lowering effects of an alternative regimen to statins(simvastatin) This alternative regimen is over the counter and available at health food stores. The alternative regimen consists of lifestyle changes including a Mediterranean Diet,exercise program, and stress reduction, with red yeast rice 1200 mg twice per day and fish oil 6 grams/day. The second group, run at the same time will take Zocor(simvastatin) 40 mg per day with standard counseling

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Simvastatin Vs Therapeutic Lifestyle Changes and Supplements: A Primary Prevention Randomized Trial
Study Start Date : April 2006
Study Completion Date : June 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Simvastatin

Primary Outcome Measures :
  1. LDL-c cholesterol

Secondary Outcome Measures :
  1. total cholesterol
  2. HDL
  3. Triglycerides
  4. cardiac CRP

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adults ages 18-75 yrs, who meet ATP III criteria to be treated for high cholesterol. All participants must be able to exercise and be willing to be randomized to either arm of the study

Exclusion Criteria:

  • No history of bypass surgery, stents, or hx of myocardial infarction. Cannot have uncontrolled hypertension(SBP>190 or DBP>100), cannot have known intolerance to one of the study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00365742

Sponsors and Collaborators
Chestnut Hill Health System
Layout table for investigator information
Principal Investigator: David Becker

Layout table for additonal information Identifier: NCT00365742     History of Changes
Other Study ID Numbers: FWA00005390-Chestnut Hill Hosp
First Posted: August 17, 2006    Key Record Dates
Last Update Posted: August 17, 2006
Last Verified: August 2006
Keywords provided by Chestnut Hill Health System:
red yeast rice
pharmaceutical grade fish oil
primary prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
Red yeast rice
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors